thyroid cancer
FDA Grants Full Approval to Eli Lilly's Retevmo in RET-Mutant Medullary Thyroid Cancer
The agency converted a prior accelerated approval to a traditional approval based on results from the LIBRETTO-531 trial.
Eli Lilly Nabs Full FDA Approval for Retevmo in RET Fusion-Positive Thyroid Cancer
In converting a 2020 accelerated approval to a full approval, the agency lowered the RET inhibitor's age restriction from 12 years old to 2 years old.
FDA Lowers Pediatric Age for Eli Lilly's Retevmo
The RET inhibitor can now be given to children with RET-altered cancers as young as 2 years old.
Eli Lilly to Share With Regulators Data on Retevmo Besting Standard Drugs in Thyroid Cancer Patients
The Phase III study data showing Retevmo improved progression-free survival in patients with RET-mutant tumors may support conversion from accelerated to full approval.
Roche, Blueprint Medicines Withdraw Gavreto in RET-Mutant Medullary Thyroid Cancer in US
Genentech has decided it will no longer pursue the confirmatory trial for Gavreto in this setting due to feasibility.
Mar 11, 2021